Close
Achema middle east
swop processing & packaging

Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Cephalon, Inc.announced that a Risk Evaluation and Mitigation Strategy (REMS) for its antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by the U.S. Food and Drug Administration (FDA). The GABITRIL REMS consists of a Medication Guide to inform patients about the potential risks associated with the use of GABITRIL. The implementation of the REMS is a result of FDA’s identification in 2008 of an increased risk of suicidal thoughts and behavior with the class of antiepileptic drugs (AEDs) which includes GABITRIL. The current product labeling already contains a warning that includes this risk. The addition of a Medication Guide for patients and ongoing assessment of the REMS program is consistent with the company’s commitment to safe and appropriate use of its medications. The GABITRIL Medication Guide will be available on the product website, www.gabitril.com, and will be dispensed with every prescription. The three-pronged REMS assessment plan will be implemented on an ongoing basis to evaluate (1) patients’ understanding of the potential serious risks associated with the medication; (2) the distribution and dispensing of the Medication Guide; and (3) adherence to distribution and dispensing requirements as well as corrective actions taken to address noncompliance. In accordance with the approved REMS, the company is currently updating all labeling related to GABITRIL to include the Medication Guide.

Latest stories

Related stories

Trump Order to Go Heavy on D2C Pharmaceutical Ads

US President Donald Trump is all set to order...

Is US Planning Executive Order on Chinese Pharma Companies?

It is worth noting that the pharmaceutical sector’s recent...

The Realities of the Nursing Shortage in Rural America

Along with multiple public health crises, the United States...

Green List by FDA to Cut Illegal GLP-1 Active Ingredients

The U.S. Food and Drug Administration has gone on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »